Replimune Group, Inc.

Replimune Group, Inc.

Biotechnology • Healthcare • Woburn, MA, United States • REPL (NMS)

Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of oncolytic immunotherapies to treat cancer. The company's proprietary oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF for a range of solid tumors. The company is also developing RP2 that express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3, which express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.

781 222 9600 500 Unicorn Park Drive, Woburn, MA 01801, United States

Stock Performance (90 Days)

Data through Dec 26, 2025
Price updates on page refresh. Intraday quotes available during market hours (9:30 AM - 4:00 PM EST).

Layoff History

No layoff events recorded for this company.

Recent News

Replimune Group (NASDAQ:REPL) Trading Up 4.8% - Should You Buy? - MarketBeat
MarketBeat • Dec 24
Replimune (REPL) Shares Tank 45% After Company Says No Pathway Identified For Lead Drug RP1, Securities Class Action Pending - Hagens Berman - PR Newswire
PR Newswire • Sep 20
Wedbush upgrades Replimune Group stock rating on FDA acceptance of BLA - Investing.com
Investing.com • Oct 20
Why Replimune Stock Plummeted by Almost 40% Today - The Motley Fool
The Motley Fool • Sep 18
Why Replimune Stock Was Soaring Today - Nasdaq
Nasdaq • Oct 20

Other Biotechnology Companies

View All →
CODEXIS, INC. logo Codexis, Inc.
1 layoff tracked
$144.5M market cap
VERTEX PHARMACEUTICALS INC / MA logo Vertex Pharmaceuticals Inc. / MA
$118.68B market cap
REGENERON PHARMACEUTICALS, INC. logo Regeneron Pharmaceuticals, Inc.
$82.72B market cap
ALNYLAM PHARMACEUTICALS, INC. logo Alnylam Pharmaceuticals, Inc.
$52.92B market cap
ARGENX SE logo Argenx SE
$52.62B market cap
INSMED Inc logo Insmed Inc.
$37.61B market cap

Frequently Asked Questions

Has Replimune Group, Inc. had layoffs?
No layoff events have been recorded for Replimune Group, Inc. in our database. This could mean the company has not conducted significant layoffs, or any layoffs have not been publicly reported.
How many employees does Replimune Group, Inc. have?
Replimune Group, Inc. has approximately 479 employees.
What industry is Replimune Group, Inc. in?
Replimune Group, Inc. operates in the Biotechnology industry, within the Healthcare sector.
Is Replimune Group, Inc. a publicly traded company?
Yes, Replimune Group, Inc. is publicly traded under the ticker symbol REPL on the NMS. The company has a market capitalization of approximately $0.78 billion.
Where is Replimune Group, Inc. headquartered?
Replimune Group, Inc. is headquartered in Woburn, MA, United States at 500 Unicorn Park Drive, Woburn, MA 01801, United States.

Disclaimer

Data aggregated from public sources including WARN notices, SEC filings, press releases, and market data. While we strive for accuracy, information is provided "as-is" for informational purposes only. Always verify critical information with official company sources.

This information does not constitute investment, financial, legal, or career advice. See our Terms of Service, Privacy Policy, and About page for more information.

Found an error? Report it here.